Optimizing Therapy for Patients Radioactive Iodine Refractory Differentiated Thyroid Cancer (RAI-R-DTC) - Episode 11
Determining Which DTC Patients May Benefit from Systemic Therapy
Hyunseok Kang, MD, discusses the importance of balancing toxicities and other factors when initiating first-line treatments for patients with refractory differentiated thyroid cancer (DTC), while emphasizing the need to set clear goals and communicate potential adverse reactions before allowing patients to make informed decisions.
Video Player is loading.
